Keyword: Chugai Pharmaceutical
Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.
Japan’s Chugai Pharmaceutical is promising that supply of an orphan drug used to treat acute promyelocytic leukemia will not be interrupted in Japan as it transfers manufacturing and distribution of it to another company.